TMCnet News

Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Third Quarter and Nine-Months Ended June 30, 2015
[July 30, 2015]

Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Third Quarter and Nine-Months Ended June 30, 2015


Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its fiscal third quarter and nine-months ended June 30, 2015 financial results after the U.S. markets close on August 6, 2015. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and Enanta's business.

Conference Call and Webcast Information
To participate in the live conference call, please dial (855) 840-0595 in the U.S. or (518) 444-4814 for international callers. A replay of the conference call will be available starting at approximately 6:30 p.m. Eastern time on August 6, 2015, through 11:59 p.m. Eastern time on August 12, 2015 by dialing (855) 859-2056 from the U.S. or (404) 537-3406 for international callers. The passcode for both the lie call and the replay is 82580357. A live audio webcast of the call and replay can be accessed by visiting the "Calendar of Events" section on the "Investors" page of Enanta's website at www.enanta.com.



About Enanta
Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes - protease (partnered with AbbVie), NS5A, and nucleotide polymerase - as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Enanta's lead protease inhibitor, paritaprevir, is part of AbbVie's recently approved HCV treatment regimens. In addition, Enanta has a preclinical program in non-alcoholic steatohepatitis, or NASH, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver.



[ Back To TMCnet.com's Homepage ]